Aptose Biosciences, Inc. (APTO) financial statements (2021 and earlier)
Company profile
| Business Address |
251 CONSUMERS ROAD TORONTO, ON M2J 4R3 |
| State of Incorp. | ON |
| Fiscal Year End | December 31 |
| SIC | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 98 | 30 | 35 | 17 | |||
| Cash and cash equivalents | 80 | 21 | 27 | 17 | |||
| Short-term investments | 18 | 10 | 8 | 0 | |||
| Prepaid expense | 1 | 0 | 1 | 1 | |||
| Other current assets | 0 | 0 | 0 | 0 | |||
| Total current assets: | 99 | 31 | 36 | 18 | |||
| Noncurrent Assets | |||||||
| Operating lease, right-of-use asset | 1 | 1 | 2 | 2 | ✕ | ||
| Property, plant and equipment | 0 | 0 | 0 | 0 | |||
| Total noncurrent assets: | 2 | 2 | 2 | 2 | |||
| TOTAL ASSETS: | 100 | 32 | 38 | 20 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities | 5 | 3 | 3 | 2 | |||
| Accounts payable | 2 | 1 | 1 | 1 | |||
| Accrued liabilities | 3 | 2 | 1 | 1 | |||
| Debt | 1 | 1 | 0 | 0 | |||
| Total current liabilities: | 6 | 4 | 3 | 3 | |||
| Noncurrent Liabilities | |||||||
| Long-term debt and lease obligation | 1 | 1 | 1 | 1 | |||
| Operating lease, liability | 1 | 1 | 1 | 1 | ✕ | ||
| Total noncurrent liabilities: | 1 | 1 | 1 | 1 | |||
| Total liabilities: | 7 | 5 | 4 | 4 | |||
| Stockholders' equity | |||||||
| Stockholders' equity attributable to parent | 94 | 27 | 34 | 15 | |||
| Common stock | 365 | 291 | 291 | 267 | |||
| Additional paid in capital | 35 | 35 | 34 | 34 | |||
| Accumulated other comprehensive loss | (4) | (4) | (4) | (4) | |||
| Accumulated deficit | (302) | (294) | (287) | (281) | |||
| Total stockholders' equity: | 94 | 27 | 34 | 15 | |||
| TOTAL LIABILITIES AND EQUITY: | 100 | 32 | 38 | 20 | |||
Income statement (P&L) ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | ||
|---|---|---|---|---|---|---|
| Operating expenses | (8) | (7) | (6) | (6) | ||
| Operating loss: | (8) | (7) | (6) | (6) | ||
| Nonoperating income | 0 | 0 | 0 | 0 | ||
| Investment income, nonoperating | 0 | 0 | 0 | |||
| Net loss available to common stockholders, diluted: | (8) | (7) | (6) | (6) | ||
Comprehensive Income ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | ||
|---|---|---|---|---|---|---|
| Net loss: | (8) | (7) | (6) | (6) | ||
| Other comprehensive income | 0 | 0 | ||||
| Comprehensive loss: | (8) | (7) | (6) | (5) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (0) | 0 | ||||
| Comprehensive loss, net of tax, attributable to parent: | (8) | (7) | (6) | (5) | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.